Difficulty: Medium
Average Score: 70%
Practice
Indicate selective catechol-O-methyltransferase inhibitor, which prolongs the action of levodopa by diminishing its peripheral metabolism:
Correct answer
C
Rationale
The correct answer is C) Tolcapone. Tolcapone is a selective catechol-O-methyltransferase (COMT) inhibitor that works by inhibiting the peripheral metabolism of levodopa. Levodopa is a precursor of dopamine used in the treatment of Parkinson's disease. By inhibiting COMT, tolcapone helps to prolong the action of levodopa in the body, leading to improved symptom control in Parkinson's disease patients.
Option A) Carbidopa is often used in combination with levodopa to prevent its peripheral metabolism by inhibiting aromatic amino acid decarboxylase (AADC) enzyme, not COMT. This combination therapy helps more levodopa reach the brain to be converted into dopamine.
Option B) Clozapine is an antipsychotic medication used to treat schizophrenia and does not have a role in inhibiting COMT to prolong levodopa's action.
Option D) Rasagiline is a monoamine oxidase-B (MAO-B) inhibitor used in the treatment of Parkinson's disease. While it helps prevent the breakdown of dopamine in the brain, it does not directly inhibit COMT to prolong levodopa's action in the periphery.
Understanding the mechanisms of action of these medications is crucial for healthcare professionals, especially those involved in the management of patients with Parkinson's disease. By knowing how different drugs affect the metabolism of levodopa, healthcare providers can make informed decisions to optimize treatment outcomes and minimize adverse effects for their patients.
Option A) Carbidopa is often used in combination with levodopa to prevent its peripheral metabolism by inhibiting aromatic amino acid decarboxylase (AADC) enzyme, not COMT. This combination therapy helps more levodopa reach the brain to be converted into dopamine.
Option B) Clozapine is an antipsychotic medication used to treat schizophrenia and does not have a role in inhibiting COMT to prolong levodopa's action.
Option D) Rasagiline is a monoamine oxidase-B (MAO-B) inhibitor used in the treatment of Parkinson's disease. While it helps prevent the breakdown of dopamine in the brain, it does not directly inhibit COMT to prolong levodopa's action in the periphery.
Understanding the mechanisms of action of these medications is crucial for healthcare professionals, especially those involved in the management of patients with Parkinson's disease. By knowing how different drugs affect the metabolism of levodopa, healthcare providers can make informed decisions to optimize treatment outcomes and minimize adverse effects for their patients.